Industry news

A Russian venture capital firm closed $200M to invest in Europe (including healthcare)

MedCity News

Runa Capital, a Moscow-based global tech-focused venture capital firm, announced yesterday the first closing of its new fund, Runa Capital II. With a target size of $200 million, the firm will continue investing in tech-based companies worldwide, focusing especially on Europe. The amount of the first closing has not been disclosed.

National Bioscience Report Reveals Positive Trends for Bioscience Industry

Melanie Sena, BioPharm International

A recent study analyzing the US bioscience industry growth over the past 11 years, through the recent recession and early economic recovery, reveals positive trends. The industry demonstrated a strong record of growth from 2001-2012.

More than 430 New Medicines in Development for Chronic Diseases

Melanie Sena, BioPharm International

According to a new report by the Pharmaceutical Research and Manufacturers of America (PhRMA), America’s biopharmaceutical research companies are developing 435 new medicines to target 15 leading chronic conditions affecting the Medicare population. These medicines in development include: 110 for diabetes, 62 for rheumatoid arthritis and osteoarthritis, 67 for Alzheimer’s disease, 61 for heart disease (i.e., heart failure, hypertension, ischemic heart disease and high cholesterol), and 40 for chronic obstructive pulmonary disease (COPD).

Russia Pharmaceuticals & Healthcare Report Q3 2014 from Monitor International

Dogital Journal

 Pharmaceutical companies will act to further localise pharmaceutical production in Russia over the medium term. 

10 Health Tech Companies Changing The World

Ilya Pozin, Forbes

Healthcare is such a bloated and bureaucratic industry that, at first glance, it might seem immune to disruption by innovators. But a new crop of tech entrepreneurs is trying to change that. Their products range from apps and social networks to robots and complex simulators. But they all share a common goal: to leverage new technology to fix an old industry.

Overcoming Clinical Challenges in BRIC Markets

Thomson Reuters

Rapidly changing markets raise potential for clinical trials in BRIC nations, despite challenges

FDA Issues Guidance on Expedited Programs for Serious Conditions

BioPharm

FDA has finalized guidance on expedited programs for drugs and biologics to treat serious conditions.  The guidance, released May 29, 2014, details four programs that the agency has designed to facilitate and expedite development and review of new drugs for the treatment of life-threatening conditions. 

Report:Positive Outlook for Investment in Global Pharma and Biotech Industry

Melanie Sena, BioPharm International

New analysis from Frost & Sullivan’s Private Equity and Venture Capital Investment reveals the total number of private equity and venture capital (PEVC) deals in the pharmaceutical and biotechnology industry decreased from 1063 in 2010 to 480 in 2013. However, while the returns from the pharmaceutical and biotechnology industry have been dwindling, they are better compared to the performance of other industries, the report finds.

Improving the efficiency of health care will free up about 140-150 billion rubles

Optimization of Health will release a significant amount of money , said the Minister of Health Veronika Skvortsova . At the current level of system performance by 2016 there may be some difficulties. However, if it significantly increase , the resource can be released about 140-150 billion rubles.

U.S.-Russia Innovation Corridor Selects Participants for Spring 2014

PR Newswire

Following a Competitive Selection Process, American Councils Announces Spring 2014 Residents in IT, biotechnology, and advanced manufacturing.